PURPOSE: To investigate the expression of sex steroid receptors in gastric cancer and to correlate their tumor expression profile with the clinicopathological parameters and overall survival of the patients. METHODS: Immunohistochemical methodology was employed in formalin-fixed paraffin-embedded sections from 86 patients with gastric carcinoma. Monoclonal antibodies against androgen (AR), estrogen (ER), and progesterone (PR) receptors were used. Survival rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed by the Cox proportional hazards model. RESULTS: Fifteen (17.4%) cases of gastric adenocarcinomas were positive for AR, two (2.3%) were positive for PR and three (3.5%) were positive for ER. Significantly higher AR expression was found in tumors with metastases to lymph nodes (P = 0.03). Patients with AR-positive tumors (AR+) had worse prognosis than (AR-) patients (median survival 9 months vs 24 months, P = 0.03). Patients with AR- and heat shock protein 27 (HSP27)-positive tumors (AR+/HSP27+) had a median survival of 6 months, whereas (AR-/HSP27-) patients had a median survival of 42 months (P = 0.017). Multivariate analysis revealed that AR expression and UICC stage were independent factors of unfavorable prognosis (P = 0.037 and P = 0.0055, respectively). CONCLUSIONS: Identification of AR-positive gastric carcinomas in gastric biopsies may warrant a more aggressive therapeutic approach and anti-androgen or AR-targeted agents may represent a novel strategy in tackling this devastating malignancy. Copyright 2004 Springer-Verlag
PURPOSE: To investigate the expression of sex steroid receptors in gastric cancer and to correlate their tumor expression profile with the clinicopathological parameters and overall survival of the patients. METHODS: Immunohistochemical methodology was employed in formalin-fixed paraffin-embedded sections from 86 patients with gastric carcinoma. Monoclonal antibodies against androgen (AR), estrogen (ER), and progesterone (PR) receptors were used. Survival rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed by the Cox proportional hazards model. RESULTS: Fifteen (17.4%) cases of gastric adenocarcinomas were positive for AR, two (2.3%) were positive for PR and three (3.5%) were positive for ER. Significantly higher AR expression was found in tumors with metastases to lymph nodes (P = 0.03). Patients with AR-positive tumors (AR+) had worse prognosis than (AR-) patients (median survival 9 months vs 24 months, P = 0.03). Patients with AR- and heat shock protein 27 (HSP27)-positive tumors (AR+/HSP27+) had a median survival of 6 months, whereas (AR-/HSP27-) patients had a median survival of 42 months (P = 0.017). Multivariate analysis revealed that AR expression and UICC stage were independent factors of unfavorable prognosis (P = 0.037 and P = 0.0055, respectively). CONCLUSIONS: Identification of AR-positive gastric carcinomas in gastric biopsies may warrant a more aggressive therapeutic approach and anti-androgen or AR-targeted agents may represent a novel strategy in tackling this devastating malignancy. Copyright 2004 Springer-Verlag
Authors: M d'Istria; S Fasano; F Catuogno; F Gaeta; L Bucci; G Benassai; F Mazzeo; G Delrio Journal: Dis Colon Rectum Date: 1986-04 Impact factor: 4.585
Authors: Neal D Freedman; Jiyoung Ahn; Lifang Hou; Jolanta Lissowska; Witold Zatonski; Meredith Yeager; Stephen J Chanock; Wong Ho Chow; Christian C Abnet Journal: Carcinogenesis Date: 2008-11-17 Impact factor: 4.944
Authors: Heather M Walline; Christine M Goudsmit; Jonathan B McHugh; Alice L Tang; John H Owen; Bin T Teh; Erin McKean; Thomas W Glover; Martin P Graham; Mark E Prince; Douglas B Chepeha; Steven B Chinn; Robert L Ferris; Susanne M Gollin; Thomas K Hoffmann; Henning Bier; Ruud Brakenhoff; Carol R Bradford; Thomas E Carey Journal: Head Neck Date: 2017-02-25 Impact factor: 3.147
Authors: Ho Sung Park; Jun Sang Bae; Sang Jae Noh; Kyung Min Kim; Ho Lee; Woo Sung Moon; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Kyu Yun Jang Journal: Transl Oncol Date: 2013-06-01 Impact factor: 4.243
Authors: Neal D Freedman; Wong-Ho Chow; Yu-Tang Gao; Xiao-Ou Shu; Bu-Tian Ji; Gong Yang; Jay H Lubin; Hong-Lan Li; Nathaniel Rothman; Wei Zheng; Christian C Abnet Journal: Gut Date: 2007-07-12 Impact factor: 23.059
Authors: Úna C Mc Menamin; Andrew T Kunzmann; Michael B Cook; Brian T Johnston; Liam J Murray; Andrew D Spence; Marie M Cantwell; Chris R Cardwell Journal: Int J Cancer Date: 2018-03-30 Impact factor: 7.396